The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

Diabetes affects millions worldwide, often triggering complications such as insulin resistance and fatty liver disease. To ...

New findings reveal a chilling link between type 2 diabetes and a hidden danger. The truth could change how we see both ...

The rise of GLP-1s, which were initially approved for diabetes management and later for obesity treatment, underscores this ...

A team of scientists has found new clues that could change how we think about aging. Their work suggests that aging might not ...

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

This simple, cost-effective tool has the potential to revolutionize type 2 diabetes care, helping millions of people ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

Broad access to new obesity drugs leads to longer, healthier lives, delivering a substantial societal return on investment, ...

ATTD conference, experts debated whether patients who use continuous glucose monitoring should aim for normal glycemia.